Multicenter phase II study of irinotecan plus weekly bolus 5-FU and high dose l-leucovorin for patients with metastatic colorectal cancer (OGSG 0201).

被引：0
|
作者：
Ishida, H [1 ]
Mishima, H [1 ]
Iwamoto, S [1 ]
Morimoto, T [1 ]
Kato, T [1 ]
Tsujinaka, T [1 ]
Furukawa, Y [1 ]
机构：
[1] Osaka Gastrointestinal Ctr, Chemotherapy Study Grp, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3718
引用
收藏
页码：298S / 298S
页数：1
相关论文
共 50 条
  • [31] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Gianluca Masi
    Lorenzo Fornaro
    Enrico Vasile
    Giacomo Allegrini
    Eloise Fontana
    Cristina Granetto
    Lisa Salvatore
    Lucia Mentuccia
    Michele Andreuccetti
    Enrico Cortesi
    Marco Merlano
    Stefano Cascinu
    Alfredo Falcone
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 559 - 566
  • [32] Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
    E Van Cutsem
    L Dirix
    J-L Van Laethem
    S Van Belle
    M Borner
    M Gonzalez Baron
    A Roth
    R Morant
    E Joosens
    G Gruia
    D Sibaud
    H Bleiberg
    British Journal of Cancer, 2005, 92 : 1055 - 1062
  • [33] Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
    Van Cutsem, E
    Dirix, L
    Van Laethem, JL
    Van Belle, S
    Borner, M
    Baron, MG
    Roth, A
    Morant, R
    Joosens, E
    Gruia, G
    Sibaud, D
    Bleiberg, H
    BRITISH JOURNAL OF CANCER, 2005, 92 (06) : 1055 - 1062
  • [34] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Loupakis, Fotios
    Masi, Gianluca
    Fornaro, Lorenzo
    Vasile, Enrico
    Allegrini, Giacomo
    Fontana, Eloise
    Granetto, Cristina
    Salvatore, Lisa
    Mentuccia, Lucia
    Andreuccetti, Michele
    Cortesi, Enrico
    Merlano, Marco
    Cascinu, Stefano
    Falcone, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 559 - 566
  • [35] 5-FLUOROURACIL, LEUCOVORIN AND IRINOTECAN (FOLFIRI) PLUS BEVACIZUMAB (BV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A MULTICENTER PHASE II TRIAL
    Cordio, S.
    Parra, Soto H. J.
    Pumo, V
    Condorelli, S.
    Latteri, F.
    Sambataro, D.
    Rosati, G.
    Aprile, G.
    Fassari, G.
    De Pauli, F.
    Rimassa, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2009, 20
  • [36] Phase II study in metastatic colorectal cancer patients treated with pharmacokinetically (PK) dose adjusted weekly or biweekly 5-fluorouracil (5-FU) regimes
    Link, K.
    Bertsch, T.
    Weigang-Koehler, K.
    Mueller, L.
    Ko, Y. -D.
    Stoetzer, O.
    Kunzmann, V.
    Suttmann, I.
    Roessler, M.
    Moritz, B.
    Salamone, S.
    Sonnenschein, U.
    Wilhelm, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 42 - 42
  • [37] Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid
    Joulia, JM
    Pinguet, F
    Ychou, M
    Duffour, J
    Astre, C
    Bressolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 296 - 301
  • [38] A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
    Hirofumi Yasui
    Kei Muro
    Yasuhiro Shimada
    Akihito Tsuji
    Shinichi Sameshima
    Hideo Baba
    Taroh Satoh
    Tadamichi Denda
    Kenji Ina
    Tomohiro Nishina
    Kensei Yamaguchi
    Taito Esaki
    Shinya Tokunaga
    Hiroyuki Kuwano
    Narikazu Boku
    Yoshito Komatsu
    Masahiko Watanabe
    Ichinosuke Hyodo
    Satoshi Morita
    Kenichi Sugihara
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 153 - 160
  • [39] A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study
    Yasui, Hirofumi
    Muro, Kei
    Shimada, Yasuhiro
    Tsuji, Akihito
    Sameshima, Shinichi
    Baba, Hideo
    Satoh, Taroh
    Denda, Tadamichi
    Ina, Kenji
    Nishina, Tomohiro
    Yamaguchi, Kensei
    Esaki, Taito
    Tokunaga, Shinya
    Kuwano, Hiroyuki
    Boku, Narikazu
    Komatsu, Yoshito
    Watanabe, Masahiko
    Hyodo, Ichinosuke
    Morita, Satoshi
    Sugihara, Kenichi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (01) : 153 - 160
  • [40] Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
    Kotake, Masanori
    Aoyama, Toru
    Munemoto, Yoshinori
    Doden, Kenji
    Kataoka, Masato
    Kobayashi, Kenji
    Nishimura, Genichi
    Fujita, Hidehito
    Nakamura, Keishi
    Takehara, Akira
    Tanaka, Chihiro
    Sakamot, Junichi
    NagatA', Naoki
    Oba, Koji
    Kondo, Ken
    ONCOLOGY LETTERS, 2017, 13 (02) : 747 - 753
12345